“…The workshop concluded that physicians have a pressing clinical need for quantitative means of measuring body storage iron that are noninvasive, safe, accurate, and readily available to improve the diagnosis and management of patients with iron overload, including those with hereditary hemochromatosis, thalassemia major, sickle cell disease, 4,8 aplastic anemia, myelodysplasia, and other disorders. Priorities in clinical research in iron overload were identified as (1) developing, calibrating, and validating new methods or modifications of current methods for quantitative measurement of tissue storage iron that are noninvasive, safe, accurate, and readily available for clinical use; (2) examining the relationship between total iron burden and manifestations of iron toxicity in different forms of iron overload-for example, hereditary hemochromatosis and transfusional iron overload in thalassemia major, sickle cell disease, aplastic and myelodysplastic anemias; (3) assessing the value of noninvasive measurements of hepatic iron in guiding iron-chelating therapy in transfusional iron overload in patients with thalassemia major, sickle cell disease, aplastic anemia, and myelodysplastic anemia and in identifying patients who would benefit from phlebotomy therapy among those found to be at genetic risk for hereditary hemochromatosis; and (4) determining the relationships between the iron concentration in specific tissues and damage to the heart, liver, pancreas, other endocrine organs, and joints in different forms of iron overload-for example, in hereditary hemochromatosis and in transfusional iron overload with thalassemia major, sickle cell disease, and aplastic and myelodysplastic anemias.…”